Skip to main content
. Author manuscript; available in PMC: 2022 Sep 30.
Published in final edited form as: Oncogene. 2022 Mar 30;41(18):2651–2662. doi: 10.1038/s41388-022-02283-0

Figure 2. G6PD is repressed by its promoter H3K9me3 deposition in human mesothelioma cells.

Figure 2.

A. RNA-Seq analysis of human mesothelioma cell line NCI-H226 treated with verticillin A. The differentially expressed genes were functionally grouped using the PANTHER program. B. The differentially expressed genes were clustered and presented. C. Western blotting analysis of LDHA and G6PD in human tumor cells treated with verticillin A for 24h. D. A malignant human mesothelioma tissue was stained with G6PD-specific antibody by immunohistochemical method. The brown color indicates G6PD protein staining, and the blue color is nucleus staining. The right panel shows an amplified area from the left panel. The red arrow points to lymphocytes. E. The indicated tumor cells were treated with verticillin A at the indicated concentrations for 24h. Histones were purified from the treated cells and analyzed by Western blotting for H3K9me3 level using anti-H3K9me3 antibody. H3 was used as normalization control. F. Top panel: The human G6PD promoter structure showing ChIP sites. Bottom panel: NCI-H226 cells were treated with verticillin A for 24h and analyzed by ChIP using H3K9me3-specific antibody. Column: Mean, Bar: SD.